Evidence map›Paper›PMID 33806075›Full record

ArticleInternational journal of molecular sciences2021

Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia.

Alfonso Martín-Bernabé, Josep Tarragó-Celada, Valérie Cunin, Sylvie Michelland, Roldán Cortés, Johann Poignant, Cyril Boyault, Walid Rachidi, Sandrine Bourgoin-Voillard, Marta Cascante and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Evaluation of AMG510 Therapy onBioengineering (Basel, Switzerland) · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Alfonso Martín-BernabéLBFA et BEeSy, Université Grenoble Alpes, Inserm, U1055, CHU Grenoble Alpes, PROMETHEE Proteomic Platform, 38000 Grenoble, France.ORCID 0000-0002-8885-6043
Josep Tarragó-CeladaDepartment of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of Universitat de Barcelona, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0001-7322-9736
Valérie CuninLBFA et BEeSy, Université Grenoble Alpes, Inserm, U1055, CHU Grenoble Alpes, PROMETHEE Proteomic Platform, 38000 Grenoble, France.
Sylvie MichellandLBFA et BEeSy, Université Grenoble Alpes, Inserm, U1055, CHU Grenoble Alpes, PROMETHEE Proteomic Platform, 38000 Grenoble, France.
Roldán CortésDepartment of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of Universitat de Barcelona, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain.
Johann PoignantReckonect, Institute for Advanced Biosciences-IAB, Université Grenoble Alpes, Inserm, UMR_S 1209/CNRS UMR 5309, 38000 Grenoble, France.
Cyril BoyaultReckonect, Institute for Advanced Biosciences-IAB, Université Grenoble Alpes, Inserm, UMR_S 1209/CNRS UMR 5309, 38000 Grenoble, France.
Walid RachidiSyMMES/CIBEST, Université Grenoble Alpes, UMR 5819 UGA-CNRS-CEA, 38000 Grenoble, France.
Sandrine Bourgoin-VoillardLBFA et BEeSy, Université Grenoble Alpes, Inserm, U1055, CHU Grenoble Alpes, PROMETHEE Proteomic Platform, 38000 Grenoble, France.ORCID 0000-0001-6511-0612
Marta CascanteDepartment of Biochemistry and Molecular Biomedicine, Institute of Biomedicine of Universitat de Barcelona, Faculty of Biology, Universitat de Barcelona, 08028 Barcelona, Spain.ORCID 0000-0002-2062-4633
Michel SeveLBFA et BEeSy, Université Grenoble Alpes, Inserm, U1055, CHU Grenoble Alpes, PROMETHEE Proteomic Platform, 38000 Grenoble, France.ORCID 0000-0001-5503-9488
Institut polytechnique de Grenoble · FRCentre National de la Recherche Scientifique · FRInstituto de Salud Carlos III · ESUniversitat de Barcelona · ES

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR1033Ministerio de Economía y Empresa SAF2017-89673-RMinisterio de Educación y Formación Profesional FPU14-05992
6 · The paper itself

Abstract

Growing evidence is showing that acetylation plays an essential role in cancer, but studies on the impact of KDAC inhibition (KDACi) on the metabolic profile are still in their infancy. Here, we analyzed, by using an iTRAQ-based quantitative proteomics approach, the changes in the proteome of

Indexed as

Cell HypoxiaA549 CellsApoptosisCarcinoma, Non-Small-Cell LungHistone Deacetylase InhibitorsHistone DeacetylasesHumansLung NeoplasmsLysineMachine LearningMetabolic Networks and PathwaysOxidative PhosphorylationOxygenProteomeProteomicsProto-Oncogene Proteins p21(ras)Histone Deacetylase InhibitorsHistone DeacetylasesKRAS protein, humanLysineOxygenProteomeProto-Oncogene Proteins p21(ras)Reactive Oxygen Speciescancer metabolismhypoxialysine deacetylase inhibitorsNSCLC

Identifiers

PMID33806075
PMCPMC8036653
OpenAlexW3138414984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.